Tag Archives: cbd white label

Xyfil Ltd   →  Blog   →  cbd white label
Author Hannah Rubery Categories CBD, E-Liquid, Regulations Posted on

Navigating CBD Advertising Rules in the UK

In the rapidly expanding world of CBD products, establishing a reputable brand name is paramount. The CBD industry in the UK, as well as in the US and EU, is teeming with competition, making it crucial for businesses to differentiate themselves. While consumer interest is on the rise, propelled by ongoing research into the potential benefits of CBD, businesses must navigate a complex landscape of advertising rules and regulations.

To thrive in such a crowded market, it's crucial to build a brand that not only produces high-quality products but also respects the legal and regulatory framework surrounding the sale and promotion of CBD. Let's delve into the intricacies of creating a reputable CBD brand in the UK, adhering to advertising rules, and fostering a reliable relationship with consumers.

The popularity of CBD in the UK

The popularity of CBD in the UK has surged significantly, mirroring global trends in the CBD industry. Much of this growth stems from increased consumer awareness and acceptance, coupled with a burgeoning body of research highlighting the potential benefits of CBD. In concrete terms, the value of the CBD market in the UK has more than doubled from £314 million in 2019, to an astonishing £690 million in 2021.

This exponential growth signifies a shift in consumer attitudes towards CBD, underscoring its acceptance into the mainstream. This surge not only underscores the potential profitability for CBD manufacturers but also the extensive opportunities that lie ahead in this booming sector. It also goes to show the competition in this industry.

Current rules in place for advertising CBD brands in the UK

In the United Kingdom, the regulation of CBD advertising falls under the purview of several regulatory bodies, most prominently, the Advertising Standards Authority (ASA) and the Food Standards Agency (FSA). CBD products are considered a food supplement and hence, manufacturers are prohibited from making any explicit health claims unless they are licensed as a medical product.

The ASA is stringent about this and has taken action against brands which have violated these guidelines. Moreover, CBD products meant for consumption, such as oils and edibles, must be registered with the FSA as a Novel Food. Complying with these rules ensures that your CBD advertising is both ethical and lawful, enhancing your brand's reputation and trustworthiness in the competitive CBD industry.

Creating your white-label CBD products with Xyfil

When it comes to manufacturing your CBD products, Xyfil offers a comprehensive white-label service that ensures your brand stands out in the crowded CBD industry. We offer end-to-end support, from the initial product development stage through to manufacturing, testing, and compliance. Our rigorous testing protocols guarantee the safety and quality of your products, while our compliance team assists with the necessary Novel Food application process with the FSA.

By partnering with us, you can focus on building your brand and marketing your products, secure in the knowledge that all regulatory aspects of production are taken care of. Partnering with Xyfil means stepping into the CBD industry with confidence and a commitment to excellence.

Conclusion

Navigating the complex landscape of the CBD industry, especially concerning advertising rules and regulations, can be challenging. However, to establish a reputable CBD brand in the UK market, adherence to these norms is non-negotiable. Balancing the promotion of your CBD products while staying within legal boundaries is intrinsic to your brand's integrity and longevity. By prioritizing thorough research, compliance, and quality production, you can elevate your brand above the competition.

Partnering with a reliable manufacturer like Xyfil can ease this journey by taking care of regulatory aspects and ensuring the quality of your products, allowing you to focus on your core mission: to provide consumers with the best CBD experience. As the CBD industry continues to grow and evolve, the brands that prioritize trust, transparency, and quality will undoubtedly lead the way.

Author Hannah Rubery Categories CBD, Compliance, Manufacturing Posted on

UK Becomes the First Country to Regulate CBD Market

The UK has recently become the first country to regulate orally consumed CBD products. Currently, CBD has been touted as a novel food group item or supplementary, but the new move to regulate CBD hopes to “de-risk” CBD (Cannabidiol) to spur innovation. With a clear set of guidelines for orally consumed CBD products, there is a growing likelihood of improvement in the sort of products offered.

In response to this move, the FSA (Food Standards Agency) and the ACI (Association for the Cannabinoid Industry) has created a list featuring CBD products. These products have been given the green light to remain on shelves in line with the UK’s new novel foods regulations. Products that do not appear on the list can no longer be sold.

Ensuring these guidelines are met by CBD products not only helps to ensure the quality and safety of products in England and Wales, but also for investors looking to take part in the CBD industry. Trading Standards will also be enforcing the new rules with immediate effect on retailers selling CBD products.

Regulating orally consumed CBD products

From February 13th, 2020, no new CBD extracts, isolates or associated final products using the novel ingredient CBD, are allowed to be sold until they receive the necessary authorisation. Products that were available beforehand were required to send an application for assessment by the FSA. The complete process of evaluation can take around a year to complete. One month is allowed for the validation process, then up to nine months for the risk assessment, and up to seven months for any subsequent risk management and authorisation decisions.

Most applicants will be manufacturers of CBD brands including us here at Xyfil. A detailed dossier must be provided for existing and new orally consumed CBD products.

There are three parts involved. Firstly, part one should contain all administrative data such as information relating to the applicant. Part two should contain information specific to the novel food (along with a list of references) such as:

  • identity of the novel food
  • production process
  • compositional data
  • specifications
  • the history of use of the novel food and/or its source
  • proposed uses and use level and anticipated intake
  • absorption, distribution, metabolism and excretion
  • nutritional information
  • toxicological information and allergenicity

Part three should include the glossary or abbreviations of terms quoted in the dossier, certifications (on the accreditation of laboratories, certificates of analyses), full copies/reprints of all pertinent scientific data (published and unpublished), full study reports and scientific opinion of national/international regulatory bodies.

Ensuring the quality of the dossier, and the information provided significantly affects the time needed for assessment and authorisation.

Xyfil makes the process simpler for you

Brands can apply for authorisation of CBD extracts and isolates via our compliance and White Label service. We will guide you through the process and secure your products ready for sale. Here at Xyfil, we have worked on countless successful applications for CBD-based products. Our market-ready approach means less paperwork and less hassle in getting your business off the ground.

By working with us you can benefit from our purpose-built analytical laboratory, including patent-pending equipment for generating accurate emissions samples. Work with our dedicated scientists and let us handle your brand compliance from end to end. Get in touch today to get started on your CBD brand.